A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies

Howard A. Burris, Charles W. Taylor, Suzanne F. Jones, +8

Clinical Cancer Research

Phase I and Pharmacokinetic Study of Lapatinib in Combination With Capecitabine in Patients With Advanced Solid Malignancies

Quincy S. Chu, Garry Schwartz, Johann S. de Bono, +9

Journal of Clinical Oncology

A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan

Rachel Midgley, Keith T. Flaherty, James Stevenson, +8

Annals of Oncology

Pharmaceutical ScienceMedicinePharmacologyPharmacokinetic StudyPharmacotherapy +5

Phase I Pharmacokinetic Study of the Safety and Tolerability of Lapatinib (GW572016) in Combination with Oxaliplatin/Fluorouracil/Leucovorin (FOLFOX4) in Patients with Solid Tumors

Wandena S. Siegel-Lakhai, Jos H. Beijnen, Walter L. Vervenne, +8

Clinical Cancer Research

Clinical activity of GW572016 in EGF10003 in patients with solid tumors

M. Versola, H. A. Burris, Sharon Jones, +6

Journal of Clinical Oncology

Vegf InhibitionSerum Vegf LevelsSolid TumorsMalignant DiseaseMedicine +13

Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer

Rogério Lilenbaum, C.-S. Chen, Tarek Chidiac, +4

Annals of Oncology

Gemcitabine Versus CarboplatinPhase IiMedicinePharmacologyBronchial Neoplasm +5

Clinical activity of GW572016 in EGF10003 in patients with solid tumors

M. Versola, H. A. Burris, Suzanne F. Jones, +6

Journal of Clinical Oncology

Vegf InhibitionSerum Vegf LevelsSolid TumorsMalignant DiseaseMedicine +13

Phase I clinical, biology & pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors

Garry Schwartz, Quincy Chu, L. A. Hammond, +7

Journal of Clinical Oncology

OncologyMedicinePharmacokinetic StudyAdvanced Solid TumorsGw 572016 +6

Phase I/II study of E7050 (golvantinib) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results.

Bert H. O’Neil, Johanna C. Bendell, Manuel Modiano, +5

Journal of Clinical Oncology

Phase I/ii StudyPathologyPharmacotherapyPre-clinical PharmacologyTranslational Pharmacology +22

A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors

Lini Pandite, Howard A. Burris, Suzanne F. Jones, +7

Journal of Clinical Oncology

Solid TumorsMedicineCancer ManagementMetronomic TherapyPharmacology +12